Principal Investigator Signature Page

NON-INTERVENTIONAL
FINAL STUDY REPORT

A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in the United States and Canada

Study Number: CMO-EPI-GI-0582
Final Report

Signatory Primary Investigator:

29 May 2020

Richard C. Dart, MD, PHD
President, Canadian Consumer Product and Pharmaceutical Safety Inc.
20 Holly Street, Suite 200, Toronto, Ontario, Canada M4S 3E8
Director, Rocky Mountain Poison & Drug Safety 777 Bannock Street, MC 0180, Denver, Colorado, United States 80204

Date

PASS information

Title	A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in the United States and Canada
Version identifier of the final study report	N/A
Date of last version of the final study report	N/A
EU PAS register number	EUPAS25247
Active substance	Eluxadoline ATC Code: A07DA06
Medicinal product	Viberzi 75 mg film-coated tablets Viberzi 100 mg film-coated tablets
Product reference	N/A
Procedure number	N/A
Marketing authorisation holder(s)	Allergan Inc. 85 Enterprise Blvd., Suite 500 Markham, Ontario Canada L6G 0B5 1-800-668-6424
Joint PASS	No
Research question and objectives	Primary Objectives: a) To quantify the rate of abuse and serious adverse events for eluxadoline during a 3-year post approval period Secondary Objectives: a) To describe characteristics in terms of exposures and patient demographics of eluxadoline exposures reported to United States and Canadian poison centers b) To describe the medical outcomes associated with eluxadoline exposures reported to United States and Canadian poison centers

Title	A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in the United States and Canada
Country(-ies) of study	Canada and United States
Author	Richard C. Dart, MD, PhD

Marketing authorisation holder(s)

Marketing authorisation holder(s)	Allergan Inc. 85 Enterprise Blvd., Suite 500 Markham, Ontario Canada L6G 0B5 1-800-668-6424
MAH contact person	Ahunna Ukah, PhD Director, Epidemiology Ahunna.ukah@allergan.com +1 916 953 9408 Rhiannon Konig Senior Manager, Regulatory Affairs Rhiannon.konig@allergan.com 905 940 7353

Approval Page, Allergan

Project Title	A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in the United States and Canada
Protocol ID Number	CMO-EPI-GI-0582
Effective Date	June 24, 2020
Author	Richard C. Dart, MD, PhD President, Canadian Consumer Product and Pharmaceutical Safety Inc. Director, Rocky Mountain Poison & Drug Safety
Version	1.0

The following people have reviewed the report and give their approval:

_____ _____

Darren Weissman, MD *Signature* Date
Assoc. VP, Medical Safety Physician
Chief Medical Office

_____ _____

Anita Bhagroo Verga, DrPH *Signature* Date
Executive Director, Epidemiology
Research and Development

_____ _____

Ilse Sjöholm, MScPharm *Signature* Date
Associate VP, EU QPPV
Pharmacovigilance and Patient Safety

Table of contents

1. Abstract

Title

A Post-Marketing Surveillance of the Abuse of Eluxadoline using Poison Centre Data in Canada and the United States

Keywords

Poison center, exposure, eluxadoline, abuse, Viberzi

Marketing Authorisation Holder(s)

AbbVie, Inc.

1400 Sheridan Rd

North Chicago, IL, United States

1-847-932-7900

Names and affiliations of principal investigators

Richard C. Dart, MD, PhD

President, Canadian Consumer Product and Pharmaceutical Safety Inc.

Director, Rocky Mountain Poison & Drug Safety

Rationale and background

Eluxadoline (Viberzi®), a mixed μ-opioid receptor agonist, δ-opioid receptor antagonist, and κ-opioid receptor agonist is approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. The use of opioid agonists is associated with potential for abuse or misuse. An overdose of eluxadoline may result in symptoms resulting from an exaggeration of the known pharmacodynamic effects of the medicinal product. Health Canada has requested that Allergan monitor the drug abuse/overdose potential of eluxadoline in the post-marketing setting. Using data from calls made to poison centers in the United States and Canada, this study describes a) the level of abuse and serious adverse events of eluxadoline since approval in the United States and Canada and b) the characteristics of exposures involving eluxadoline in the United States and Canada.

Primary Objectives

a) To quantify the rate of abuse and serious adverse events for eluxadoline during a 3-year post approval period

Secondary Objectives

a) To describe characteristics in terms of exposures and patient demographics of eluxadoline exposures reported to United States and Canadian poison centers

b) To describe the medical outcomes associated with eluxadoline exposures reported to United States and Canadian poison centers

Study design

Retrospective observational surveillance study using data from the National Poison Data System in the United States and the Canadian Poison Centre Network Program in Canada.

Setting

Telephone calls received from the general public and healthcare professionals to poison centers for the reporting and management of poison related exposures or injuries.

Subjects and study size, including dropouts

All cases of human exposure to eluxadoline recorded in the National Poison Data System as originating in the United States during a 3-year period (January 2017 to December 2019) were identified and included in the analysis. All cases of human exposure to eluxadoline recorded in the Canadian Poison Centre Network Program during a 2-year period (January 2018 to December 2019) were identified and included in the analysis.

Variables and data sources

Secondary data collected by the National Poison Data System were used. They include:

- Patient demographics (age, gender)
- Number of substances involved in exposure
- Reason for exposure (intentional, unintentional, intentional abuse, intentional misuse, pediatric unintentional general)
- Route of exposure (ingestion, inhalation/nasal, parenteral, other, unknown) for single substance exposures (eluxadoline exposures only)
- Major medical outcome, hospitalization, or death (serious adverse event)
- Medical outcomes (no effect/minor effect/moderate effect/major effect/death/no follow-up)

Results

- In total there were 123 exposures involving eluxadoline reported to poison centers in the United States from 2017 through 2019.

- Of the 123 exposures involving eluxadoline reported to poison centers in the United States, no intentional abuse exposures were reported, and 14 exposures categorized as a serious adverse event were reported. One death was reported.
- The majority of exposures (N=86, 70%) were unintentional.
- There were 16 (13.0%) unintentional pediatric exposures.
- Almost all exposures were via the ingestion route of administration except 1 case with an unknown route of exposure.
- There were zero exposures involving eluxadoline reported in the Canadian Poison Centre Network in 2018 and 2019.

Discussion

There were no intentional abuse exposures mentioning eluxadoline in Canada or the United States. Fourteen exposures resulting in serious adverse events were reported and all were located in the United States. The majority of eluxadoline exposures were unintentional; 16 involved pediatric patients. There were no exposures involving eluxadoline regardless of motivation reported in Canada.